Helical Tomotherapy in Multiple Myeloma

Recruiting now · Not applicable

Conditions studied: Multiple Myeloma

In brief

To explore the safety and efficacy of systemic radiotherapy (TBI) combined with melphalan (Mel) for pretreatment of autologous hematopoietic stem cells in multiple myeloma.

Key facts

Study ID

NCT05970198

Run by

Fuling Zhou

People needed

58

Starts

2023-06-14

Expected to finish

2027-12-31

Last updated by the study team

2023-08-01

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Multiple myeloma patients receiving induction therapy and stem cell mobilization preparation for autologous transplantation;
• Should agree to comply with all contraceptive requirements; 3, ECOG≤2;
• Total bilirubin, ALT and AST <2×UNL (upper limit of normal), BUN < 30 mg/dL; 5. At least 2 x 10\^6 CD34+ cells /kg were collected; 6.absolute neutrophil count >1000/uL and a platelet count of >100,000/uL; 7. The expected survival time is more than 3 months; 8. Written informed consent was obtained from the patients or their immediate family members.

You may not qualify if…

• Any of the following was an exclusion criterion:
• According to the investigator's judgment, patients who cannot tolerate melphalan and radiotherapy;
• Patients with known active hepatitis B virus (HBV) or hepatitis C virus (HCV), or seropositive for human immunodeficiency virus (HIV);
• patients with uncontrolled or severe cardiovascular disease
• According to the protocol or the investigator's judgment, the patient has a serious physical or mental illness

Where it is running

• Zhongnan Hospital of Wuhan University — Wuhan, Hubei, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.